MedTrace Logo

A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors

NCT06130553 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 334

Last updated 2026-05-11

No results posted yet for this study

Summary

This is a first time in human (FTiH) Phase I/IIa, open-label, multi-centre study of AZD3470 in participants with advanced or metastatic solid tumors with MTAP deficiency. The study consists of several study modules, evaluating the safety, tolerability, pharmacokinetic (PK), pharmacodynamics, and preliminary efficacy of AZD3470 as monotherapy or in combination with other anti-cancer agents.

Conditions

  • Advanced Solid Tumors That Are MTAP Deficient

Interventions

DRUG

AZD3470

AZD3470 is a novel, potent and selective, second-generation, MTAP-selective, inhibitor of PRMT5.

DRUG

Datopotamab deruxtecan

AZD3470 in combination with Dato-DXd + Dato-Dxd monotherapy

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-18
Primary Completion
2028-12-04
Completion
2028-12-04
FDA Drug
Yes

Countries

  • United States
  • Australia
  • China
  • France
  • Japan
  • Netherlands
  • South Korea
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06130553 on ClinicalTrials.gov